Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome

22Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Turner syndrome (TS) has been included for several years among the indications for GH treatment, generally with satisfactory outcomes. Nevertheless, the long-term effects of this treatment in non-GH deficient patients are not fully known. The incidence of thyroid carcinoma is rare in patients during childhood, it is unusual to find this neoplasia in children under sixteen years old. This article reports the cases of two Spanish patients with papillary thyroid carcinoma after GH treatment for TS. Recent studies have indicated a possible relationship between the GH-IGF axis and the pathogenesis of neoplasias, questioning the chance association of these two pathologies. In line with this, we detected GH receptor expression in the papillary carcinoma cells. Long-term prospective studies are required to clarify the possible effects of GH treatment on the risk of neoplasia. © 2005 Society of the European Journal of Endocrinology.

Cite

CITATION STYLE

APA

Cabanas, P., García-Caballero, T., Barreiro, J., Castro-Feijóo, L., Gallego, R., Arévalo, T., … Pombo, M. (2005). Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome. European Journal of Endocrinology, 153(4), 499–502. https://doi.org/10.1530/eje.1.01988

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free